Milestone Pharmaceuticals Inc. Logo

Milestone Pharmaceuticals Inc.

Developing a self-administered nasal spray for at-home treatment of acute cardiac events.

MIST | US

Overview

Corporate Details

ISIN(s):
USU6005B1045 (+1 more)
LEI:
549300P43IPGW3Q3Y026
Country:
United States of America
Address:
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, 07039 MONTREAL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for episodic cardiovascular conditions. The company's lead investigational product is etripamil, a proprietary, novel calcium channel blocker delivered as a self-administered nasal spray. This therapy is designed for the rapid termination of paroxysmal supraventricular tachycardia (PSVT) episodes in an at-home setting, addressing a significant unmet need for treatment outside of the emergency department. Milestone is also exploring etripamil's potential for other conditions, such as atrial fibrillation with rapid ventricular rate (AFib-RVR), to provide patients with control over acute cardiac events.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Milestone Pharmaceuticals Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Milestone Pharmaceuticals Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Milestone Pharmaceuticals Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SANIGEN Co., Ltd. Logo
Provides food safety solutions and genetic diagnostics for the entire food industry.
South Korea
188260
Sanofi Logo
Global biopharma firm researching, developing & marketing prescription medicines & vaccines.
France
SAN
SANTEN PHARMACEUTICAL CO.,LTD. Logo
A global ophthalmology specialist developing drugs and devices for glaucoma, dry eye, and infections.
Japan
4536
Santhera Pharmaceuticals Holding AG Logo
Develops innovative medicines for rare neuromuscular and mitochondrial disorders.
Switzerland
SANN
Sarepta Therapeutics, Inc. Logo
Develops precision genetic medicines for rare neuromuscular disorders.
United States of America
SRPT
Savara Inc Logo
Clinical-stage biopharma developing inhaled therapies for rare respiratory diseases.
United States of America
SVRA
SAWAI GROUP HOLDINGS Co., Ltd. Logo
A leading Japanese generic drug maker expanding into digital health and wellness solutions.
Japan
4887
Scandion Oncology A/S Logo
Biotech company in liquidation, formerly developing therapies to overcome cancer drug resistance.
Denmark
SCOL
Scholar Rock Holding Corp Logo
Biopharma developing medicines for neuromuscular diseases by targeting protein growth factors.
United States of America
SRRK
Scienture Holdings, Inc. Logo
Develops and commercializes specialty drugs for unmet medical needs, focusing on CNS disorders.
United States of America
SCNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.